Chronic Lymphocytic Leukemia (CLL): From Benchside to Bedside

A special issue of Lymphatics (ISSN 2813-3307).

Deadline for manuscript submissions: 31 January 2025 | Viewed by 235

Special Issue Editor


E-Mail Website
Guest Editor
MD Anderson Cancer Centerdisabled, University of Texas, Houston, TX, USA
Interests: lymphoma; chronic lymphocytic leukemia; translational research; transcription inhibitors; therapeutics for leukemias

Special Issue Information

Dear Colleagues,

This Special Issue of the Lymphatics journal aims to enable the rapid publication of contributions and discoveries concerning all aspects of chronic lymphocytic leukemia (CLL) research, ranging from basic research to clinical applications, with the focus on the translational research.

In the past few decades, with the new understanding of pathogenesis and molecular biology of CLL, the prognosis tools and targeted therapies have been greatly developed. However, it is still far from sufficient to reach robust conclusions and guidelines for treatment. We are pleased to invite you to share with us your perspectives and research results of CLL in the Collection. Topics include, but are not limited to, the following:

- Normal B-cells and CLL B-cells

- Genetics and genomics of CLL

- Microenvironment

- Molecular biology, pathology and diagnostics

- Therapeutics, chemotherapy and chemoimmunotherapy

- Therapeutics, novel targeted therapies including cellular therapies

- Resistance mechanisms

- Curing CLL

Prof. Dr. Varsha Gandhi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Lymphatics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • B-cells
  • BTK
  • Bcl-2
  • chemoimmunotherapy
  • CLL
  • cure
  • microenvironment
  • resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop